Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count.

MLA

Bachert, Claus, et al. “Mepolizumab for Chronic Rhinosinusitis with Nasal Polyps: Treatment Efficacy by Comorbidity and Blood Eosinophil Count.” The Journal of Allergy and Clinical Immunology, vol. 149, no. 5, May 2022, p. 1711. EBSCOhost, https://doi.org/10.1016/j.jaci.2021.10.040.

APA

Bachert, C., Sousa, A. R., Han, J. K., Schlosser, R. J., Sowerby, L. J., Hopkins, C., Maspero, J. F., Smith, S. G., Kante, O., Karidi-Andrioti, D. E., Mayer, B., Chan, R. H., Yancey, S. W., & Chaker, A. M. (2022). Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count. The Journal of Allergy and Clinical Immunology, 149(5), 1711. https://doi.org/10.1016/j.jaci.2021.10.040

Chicago

Bachert, Claus, Ana R Sousa, Joseph K Han, Rodney J Schlosser, Leigh J Sowerby, Claire Hopkins, Jorge F Maspero, et al. 2022. “Mepolizumab for Chronic Rhinosinusitis with Nasal Polyps: Treatment Efficacy by Comorbidity and Blood Eosinophil Count.” The Journal of Allergy and Clinical Immunology 149 (5): 1711. doi:10.1016/j.jaci.2021.10.040.